The aldo-keto reductase (AKR) superfamily is a rapidly growing group of NAD(P)(H)-dependent oxidoreductases that metabolize carbohydrates, steroids, prostaglandins, and other endogenous aldehydes and ketones, as well as xenobiotic compounds.
-3-ketosteroid-5b-reductases; and AKR1E) mouse keto-reductase. The subfamilies are defined by a Ͼ60% identity in amino acid sequence among subfamily members, but the AKR1C subfamily includes some members that have not been studied as to their enzymatic properties or functions. One such member is AKR1C19 that was found by mouse genomic analysis and cDNA isolation from the liver and gastrointestinal tract.
3) Although AKR1C19 is postulated to be a 3 (20) a-HSD-like enzyme based on its highest sequence identity (72%) with human 3(20)a-HSD (AKR1C1) in the AKR1C subfamily, 2) a mouse counterpart of AKR1C1 is shown to be an NADP(H)-dependent 3a/3b/20a-HSD (AKR1C18), 4, 5) which shares a lower sequence identity (65%) with AKR1C19. To determine the functional relationship of AKR1C19 with AKR1C18, we examined the enzymatic properties of the recombinant AKR1C19.
MATERIALS AND METHODS
Chemicals Prostaglandins were obtained from Cayman Chemicals (Ann Arbor, MI, U.S.A.), steroids were from Sigma Chemicals and Steraloids (Newport, RI, U.S.A.), and resins for column chromatography were from Amersham Biosciences (Piscataway, NJ, U.S.A.). trans-Benzene dihydrodiol was synthesized by the method of Platt and Oesch. 6) a-and b-3-Hydroxyhexobarbitals (3HBs) were gifts from Dr. R. Takenoshita (University of Fukuoka, Japan). All other chemicals were of the highest grade that could be obtained commercially.
cDNA Isolation The cDNA for AKR1C19 was amplified by reverse transcription (RT)-PCR from the total RNA of an 8-week-old male ICR mouse liver. The preparation of the total RNA and RT were carried out as described previously. 7) PCR was performed with Pfu DNA polymerase (Stratagene). The sense primer (5Ј-ATGAGTTCCAAACAGCAA) and antisense primer (5Ј-ACTAAAATTCATCAGAAAAG) correspond to positions 1-18 and 954-973, respectively, of the sequence of a transcript of the AKR1C19 gene. The PCR products of 973 base pairs were ligated into pCR T7/CT-TOPO vectors (Invitrogen), and the expression constructs were transfected into Escherichia coli BL21 (DE3) pLysS according to the protocol described by the manufacturer. The inserts of the cloned cDNAs were sequenced using a CEQ2000XL DNA sequencer (Beckman Coulter) to confirm that the deduced amino acid sequences of the cDNAs are identical to that of AKR1C19 reported by Vergnes et al.
3)

Expression and Purification of Recombinant Protein
The E. coli cells were cultured in a LB medium containing ampicillin (50 mg/ml) at 37°C until the absorbance at 600 nm reached 0.5. Then isopropyl 1-thio-b-D-galactopyranoside (1 mM) was added, the culture was continued for 24 h at 20°C. The cells were collected and the extract was prepared as described previously.
7) The recombinant AKR1C19 was purified at 4°C by (NH 4 ) 2 SO 4 fractionation and subsequent three column chromatography steps. The enzyme fraction, precipitated between 35 and 75% (NH 4 ) 2 SO 4 saturation, was dialyzed against Buffer A (10 mM Tris-HCl, pH 7.5, 5 mM 2-mercaptoethanol, 1 mM EDTA and 20% glycerol), and was applied to a Sephadex G-100 column (3ϫ70 cm) equilibrated with Buffer A. The enzyme fraction was applied to a QSepharose column (2ϫ20 cm) equilibrated with Buffer A. This enzyme eluted with a linear gradient of 0-0.1 M NaCl was dialyzed against Buffer A, and applied to a Red-Sepharose column (1.5ϫ5 cm) equilibrated with the same buffer. The column was washed with Buffer A containing 0.1 M NaCl, and the enzyme was eluted with Buffer A containing 2 mM NAD ϩ and 0.1 M NaCl. Assay of Enzyme Activity Reductase and dehydrogenase activities of AKR1C19 were assayed by measuring the rate of change in NAD(P)H absorbance (at 340 nm) and its fluorescence (at 455 nm with an excitation wavelength of 340 nm), respectively. The standard reaction mixture for the reductase activity consisted of 25 mM Tris-HCl buffer, pH 7.4, 0.1 mM NADH, substrate and enzyme, in a total volume of 2.0 ml. To detect low activities in the cell extract and enzyme preparations during the purification, 0.1 M potassium phosphate buffer, pH 6.0, was employed instead of the TrisHCl buffer. Isatin (0.1 mM) was used as the substrate, unless otherwise noted. The dehydrogenase activity was determined in 25 mM Tris-HCl, pH 7.4, containing 1 mM NAD ϩ and an appropriate amount of alcohol substrate. One unit (U) of enzyme activity was defined as the amount that catalyzes the reduction or formation of 1 mmol NADH per minute at 25°C. The apparent K m and k cat values were determined over a range of five substrate concentrations at a saturating concentration of coenzyme by fitting the initial velocities to the Michaelis-Menten equation. The kinetic constants and IC 50 (inhibitor concentrations required for 50% inhibition) values are expressed as the means of two determinations. Protein concentration was determined by the method of Bradford 8) using bovine serum albumin as the standard.
RESULTS AND DISCUSSION
Purification of Expressed AKR1C19 SDS-PAGE analysis of the E. coli cell extracts (Fig. 1) shows that the cells transfected with the expression plasmids harboring the AKR1C19 cDNA overexpresses a 36-kDa protein, which was not present in the control cells transfected with the vector alone. This cell extract exhibited NADH-linked reductase activity towards isatin (0.0032 U/mg). The recombinant AKR1C19 was purified by both detecting the 36-kDa protein on SDS-PAGE and assaying the isatin reductase activity. The enzyme was eluted at a low molecular weight of approximately 35 kDa on the Sephadex G-100 chromatography step, suggesting its monomeric nature. The final preparation with isatin activity of 0.53 U/mg was greater than 99% pure (Fig.  1) , and the purification yield was 26% (17 mg/l of cells).
pH Dependency The NADH-linked isatin reductase activity of the purified AKR1C19 was increased by decreasing the pH from 8.0 to 6.0 in 0.1 M phosphate buffers. The activity was also influenced by species and concentrations of the assay buffer. For example, the activities assayed in 0.1 M Tris-HCl buffers (pH 7.2-8.0) were higher (approximately 1.5-fold) than those assayed in 0.1 M phosphate buffers, and further increased to a maximum of 1.2-fold by lowering the buffer concentration to 25 mM. In the reverse reaction with NAD ϩ as the coenzyme, the enzyme oxidized a-3HB and the maximal rate was observed at pH 7.5 when 25 mM Hepes and Tris-HCl buffers were used. Therefore, the enzymatic properties of AKR1C19 were examined at a physiological pH of 7.4 using 25 mM Tris-HCl buffer.
Coenzyme Specificity The recombinant AKR1C19 displayed dual coenzyme specificity for NAD(H) and NADP(H). The K m and k cat /K m values for NADH determined in the presence of 0.1 mM S-camphorquinone were 6.9 mM and 3.3 min Ϫ1 mM
Ϫ1
, respectively, and the respective values for NADPH were 11 mM and 2.8 min Ϫ1 mM Ϫ1 . In the reverse reaction with 2 mM a-3HB as the substrate, NAD ϩ (K m ϭ 32 mM and k cat /K m ϭ0.61 min Ϫ1 mM
) was a better coenzyme than NADP ϩ (K m ϭ153 mM and k cat /K m ϭ0.017 min Ϫ1 mM
). Since the intracellular ratio of NAD ϩ to NADH is high in contrast to the low NADP ϩ /NADPH ratio, 9) the effects of NAD ϩ on the NADH-linked and NADPH-linked reductase activities of AKR1C19 were examined. The NADPH-linked reductase activity was potently inhibited by NAD ϩ even at a low concentration of 0.1 mM, whereas the inhibition of the NADH-linked activity was low, and about 50% of the activity retained at a cellular NAD ϩ concentration of 2 mM 9) (Fig. 2) . It is likely that the enzyme acts as both NADH-linked reductase and NAD NADPH-linked activities suggests that the affinity for NADH is much higher than that for NADPH, although the apparent K m values for the two coenzymes are similar. The preference for NAD(H) over NADP(H) may be due to the presence of glutamine and aspartic acid at positions 270 and 276, respectively, which are conserved in NAD(H)-preferring members of the AKR1C subfamily and are thought to interact with the adenine ribose of the coenzyme.
10)
Substrate Specificity The purified recombinant AKR1C19 reduced several a-dicarbonyl compounds, and the catalytic efficiency (k cat /K m ) for alicyclic and aromatic substrates was higher than that for aliphatic substrates such as dimethyl-2-oxoglutarate and 2,3-hexanedione (Table 1) . While isatin and 5-bromoisatin were good substrates, 1-phenylisatin, a substrate of AKR1C18, 5) was not reduced. The enzyme showed less than 5% of the isatin reductase activity towards 1 mM of other a-dicarbonyl compounds (methylglyoxal, diacetyl and 3,4-hexanedione) and monocarbonyl compounds (4-nitrobenzaldehyde, pyridine-4-aldehyde, 4-nitroacetophenone, 4-benzoylpyridine), which are efficiently reduced by AKR1C18, 5) mouse 3(17)a-HSD (AKR1C21), 11) mouse 17b-HSD (AKR1C6), 12, 13) AKR1C1, 14, 15) and/or human 3a-HSDs (AKR1C2 and AKR1C4). 14, 16) In this respect, AKR1C19 also differs from other members of the AKR superfamily such as aldehyde reductase, aldose reductase 17) and aflatoxin B1 aldehyde reductase 14) with broad substrate specificity for a variety of carbonyl compounds. AKR1C19 was inactive towards various ketosteroid substrates of the above HSDs, sugars (D-glyceraldehyde, D-xylose, D-glucose and D-glucuronate) and prostaglandin D 2 , a representative substrate of human and bovine prostaglandin F synthases (AKR1C3 and AKR1C11). 18, 19) In the reverse reaction, AKR1C19 oxidized a-and b3HBs, S-indan-1-ol and cis-benzene dihydrodiol, but the catalytic efficiency for the substrates was lower compared to that in the reductase reaction. The enzyme was inactive towards S-tetralol, R-indan-1-ol, trans-benzene dihydrodiol and 9a,11b-prostaglandin F 2 , which are non-steroidal substrates for the above HSDs and prostaglandin F synthases of the AKR1C subfamily. The enzyme was also inactive towards hydroxysteroid substrates of the above HSDs belonging to the AKR1C subfamily and sugars such as D/L-threitols, mesoerythritol, D/L-arabitols, ribitol, xylitol, inositol, dulcitol, Dsorbitol and D-xylose.
Inhibitor Sensitivity The reductase activity of AKR1C19 towards 0.1 mM S-camphorquinone was inhibited by dicumarol, lithocholic acid and genistein (IC 50 values were 1.9, 5.7 and 56 mM, respectively). No significant inhibition (less than 25%) was observed by 5 mM benzbromarone, 10 mM medroxyprogesterone acetate, 50 mM dexamethasone, hexestrol, diethylstilbestrol, indomethacin, phenolphthalein, fulfenamic acid or 0.1 mM 1,10-phenanthroline (data not shown), which are potent inhibitors of HSDs and/or prostaglandin F synthases of the AKR1C subfamily. Thus, the inhibitor sensitivity is an additional characteristic of AKR1C19.
Roles of AKR1C19 The substrate specificity indicates that AKR1C19 is not a HSD, in contrast to its previously postulated function as a HSD. Among the substrates of this enzyme, only isatin is an endogenous component, which is produced through indole supplied by metabolism of tryptophan and/or phenylalanine in intestinal bacteria. 21) Since isatin has been shown to inhibit monoamine oxidase and acetylcholinesterase, and to exhibit various pharmacological actions, 20, 21) it must be metabolized into inactive metabolites. In mice, NADP(H)-dependent AKR1C18, 5) aflatoxin B 1 aldehyde reductase (AKR7A4), 22) carbonyl reductases 23) and Lxylulose reductase 24) have been shown to reduce isatin. However, AKR1C19 differs from the known isatin-reducing enzymes with respect to tissue distribution, in that its mRNA is specifically expressed in the gastrointestinal tract and liver. 3) AKR1C19 may play a role in the reductive metabolism of isatin in the gastrointestinal tract. Alternatively, it can be involved in the gastrointestinal detoxification of chemically reactive a-dicarbonyl compounds that are ingested with foods. From the point of view of drug metabolism, it is interesting that the K m values for a-and b-3HBs of AKR1C19 are comparable to those of mouse liver 3HB dehydrogenase, which has been suggested to be identical to NADP ϩ -preferring 17b-HSD (AKR1C6). 25) AKR1C19 is clearly different from the previously known 3HB dehydrogenase with respect to the specificity for coenzymes and other substrates, and is a new type of 3HB dehydrogenase. 
